Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) Gross Margin (2019 - 2025)

Bioadaptives' Gross Margin history spans 7 years, with the latest figure at 72.72% for Q4 2025.

  • Quarterly results put Gross Margin at 72.72% for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was 68.37% (up 3656.0% YoY), and the annual figure for FY2025 was 68.37%, up 3656.0%.
  • Gross Margin for Q4 2025 was 72.72% at Bioadaptives, down from 83.14% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 83.14% in Q3 2025 to a low of 25.85% in Q4 2022.
  • The 5-year median for Gross Margin is 55.25% (2021), against an average of 49.48%.
  • The sharpest move saw Gross Margin surged 5107bps in 2021, then crashed -3053bps in 2025.
  • Year by year, Gross Margin stood at 29.65% in 2021, then fell by -13bps to 25.85% in 2022, then surged by 45bps to 37.48% in 2023, then skyrocketed by 70bps to 63.56% in 2024, then rose by 14bps to 72.72% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 72.72%, 83.14%, and 33.02% for Q4 2025, Q3 2025, and Q2 2025 respectively.